<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1211246198
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MIRZAGEN 30 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MIRTAZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        78.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Mirzagen tablet is and what it is used for?</strong></p><p>Mirzagen is one of a group of medicines called&nbsp;antidepressants.</p><p>Mirzagen tablets are used to treat depressive illness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>Suicidality and Antidepressants</strong></p><p>Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorders (MDD) and other psychiatric disorders. Anyone considering the use of Mirzagen (mirtazapine) Tablets or any other antidepressant in a child, adolescent, or young adult must balance the risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in the risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increase in the risk of suicide. Patients of all ages who are started on antidepressants therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. MIRZAGEN is not approved for use in pediatric patients.</p></td></tr></tbody></table><p><strong>Do not take Mirzagen tablets</strong></p><ul><li>&nbsp;If you are&nbsp;allergic&nbsp;(hypersensitive) to Mirzagen or any of the other ingredients of Mirzagen tablets. If so, you must talk to your doctor as soon as you can before taking Mirzagen tablets.</li><li>&nbsp;If you are taking or have recently taken (within the last two weeks) medicines called monoamine oxidase inhibitors (MAO-Is).</li><li>&nbsp;If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking Mirzagen or other medicinal product(s).</li></ul><p><strong>Take special care with Mirzagen</strong></p><p><strong>Use in children and adolescents under 18 years of age</strong></p><p>Mirzagen should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe Mirzagen for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed Mirzagen for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking Mirzagen. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioural development of Mirzagen in this age group have not yet been demonstrated.</p><p><strong>Thoughts of suicide and worsening of your depression</strong></p><p>If you are depressed you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this:</p><ul><li>If you have previously had thoughts about killing or harming yourself.</li><li>If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric condition who were treated with an antidepressant.</li></ul><p>If you have thoughts or harming of killing yourself at any time, contact your doctor or go to a hospital straight away.</p><p><strong>You may find it helpful to tell a relative or close friend&nbsp;</strong>that you are depressed, and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.</p><p><strong>Also take special care with Mirzagen</strong></p><p>- If you have, or have ever had one of the following conditions. Tell your doctor about these conditions before taking Mirzagen, if not done previously.</p><ul><li><strong>Seizures</strong>&nbsp;(epilepsy). If you develop seizures or your seizures become more frequent, stop taking Mirzagen and contact your doctor immediately;</li><li><strong>Liver disease</strong>,&nbsp;including jaundice. If jaundice occurs, stop taking Mirzagen and contact your doctor immediately;</li><li><strong>Kidney disease&nbsp;;</strong></li><li><strong>Heart disease</strong>,&nbsp;or&nbsp;<strong>low blood pressure</strong>;</li><li><strong>Schizophrenia</strong>.&nbsp;If psychotic symptoms, such as paranoid thoughts become more frequent or severe, contact your doctor straight away;</li><li><strong>Manic</strong> <strong>depression</strong>&nbsp;(alternating periods of feeling elated/overactivity and depressed mood). If you start feeling elated or over-excited, stop taking Mirzagen and contact your doctor immediately;</li><li><strong>Diabetes</strong>&nbsp;(you may need to adjust your dose of insulin or other antidiabetic medicines);</li><li><strong>Eye disease</strong>,&nbsp;such as increased pressure in the eye (glaucoma);</li><li><strong>Difficulty in passing water</strong>&nbsp;(urinating), which might be caused by an enlarged prostate.</li></ul><p>- If you develop signs of infection such as unexplainable high fever, sore throat and mouth ulcers.</p><p>o&nbsp;&nbsp; Stop taking Mirzagen and consult your doctor immediately for a blood test. In rare cases these symptoms can be signs to disturbances in blood cell production in the bone marrow. While rare, these symptoms most commonly appear after 4-6 weeks of treatment.</p><p>- If you are an elderly person you could be more sensitive to the side-effects of antidepressants</p><p>- Conditions which need supervision as Endocrine disorders: hyperprolactinemia (and related symptoms, e.g., galactorrhea and gynecomastia).</p><p>- Serious skin reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of Mirzagen .Stop using and seek medical attention immediately if you notice any of the symptoms described in section 4 in relation to these serious skin reactions. If you have ever developed any severe skin reactions, treatment with Mirzagen should not be restarted.</p><p><strong>Taking other medicines</strong></p><p>Tell your doctor or pharmacist if you are taking (or plan to take) any of the medicines in the following list:</p><p>Please also tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Do not take Mirzagen&nbsp;in combination with:</strong></p><ul><li>Monoamine oxidase inhibitors&nbsp;(MAO inhibitors). Also, do not take Mirzagen during the two weeks after you have stopped taking MAO inhibitors. If you stop taking Mirzagen, do not take MAO inhibitors during the next two weeks either.</li></ul><p>Examples of MAO inhibitors are moclobemide, tranylcypromine (both are antidepressants) and selegiline (used for Parkinson&#39;s disease).</p><p><strong>Take care when</strong>&nbsp;taking Mirzagen in combination with:</p><ul><li>Antidepressants such as SSRls, venlafaxine and L-tryptophan, or triptans&nbsp;(used to treat migraine),&nbsp;tramadol&nbsp;(a pain-killer),&nbsp;linezolid&nbsp;(an antibiotic),&nbsp;lithium&nbsp;(used to treat some psychiatric conditions)&nbsp;and St. John&#39;s Wort - Hypericum perforatum preparations&nbsp;(a herbal remedy for depression). In very rare cases Mirzagen alone or the combination of Mirzagen with these medicines, can lead to a so-called serotonin syndrome. Some of the symptoms of this syndrome are: inexplicable fever, sweating, increased heart rate, diarrhoea, (uncontrollable) muscle contractions shivering, overactive reflexes, restlessness, mood changes, and unconsciousness. If you get a combination of these symptoms, talk to your doctor immediately.</li><li>The antidepressant nefazodone.&nbsp;It can increase the amount of Mirzagen in your blood. Inform your doctor if you are using this medicine. It might be needed to lower the dose of Mirzagen, or when use of nefazodone is stopped, to increase the dose of Mirzagen again.</li><li><strong>Medicines for anxiety or insomnia</strong>&nbsp;such as benzodiazepines;</li><li><strong>Medicines for schizophrenia</strong>&nbsp;such as olanzapine;</li><li><strong>Medicines for allergies</strong>&nbsp;such as cetirizine;</li><li><strong>Medicines for severe pain</strong>&nbsp;such as morphine.</li></ul><p>In combination with these medicines Mirzagen can increase the drowsiness caused by these medicines.</p><ul><li><strong>Medicines for infections</strong>:&nbsp;medicines for bacterial infections (such as erythromycin); medicines for fungal infections (such as ketoconazole) and medicines for HIV/AIDS (such as HIV protease inhibitors).</li></ul><p>In combination with Mirzagen these medicines can increase the amount of Mirzagen in your blood. Inform your doctor if you are using these medicines. It might be needed to lower the dose of Mirzagen, or when these medicines are stopped, to increase the dose of Mirzagen again.</p><ul><li><strong>Medicines for epilepsy</strong>&nbsp;such as carbamazepine and phenytoin;</li><li><strong>Medicines for tuberculosis</strong>&nbsp;such as rifampicin.</li></ul><p>In combination with Mirzagen these medicines can reduce the amount of Mirzagen in your blood. Inform your doctor if you are using these medicines. It might be needed to increase the dose of Mirzagen, or when these medicines are stopped to lower the dose of Mirzagen again.</p><ul><li><strong>Medicines to prevent blood clotting</strong>&nbsp;such as warfarin.</li></ul><p>Mirzagen can increase the effect, of warfarin on the blood. Inform your doctor if you are using this medicine. In case of combination it is advised that a doctor monitors your blood carefully.</p><ul><li><strong>Medicines that may affect</strong> the heart&rsquo;s rhythm such as certain antibiotics and some antipsychotics.</li></ul><p><strong>Taking Mirzagen tablets with food and drink</strong></p><p>You are advised not to drink any alcohol.</p><p>You may get drowsy if you drink alcohol while you are taking Mirzagen.</p><p>You can take Mirzagen tablets with or without food.</p><p><strong>Pregnancy and breast feeding</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Limited experience with Mirzagen administration to pregnant women does not indicate an increased risk. However, caution should be exercised when use during pregnancy.</p><p>If you are taking Mirzagen tablets and you become pregnant or you plan to get pregnant, ask your doctor whether you may continue taking Mirzagen tablets. If you use Mirzagen tablets until, or shortly before birth, your baby should be supervised for possible adverse effects.</p><p>Ask your doctor whether you can breast-feed, while taking Mirzagen tablets.</p><p><strong>Driving and using machines</strong></p><p>Mirzagen tablets can affect your concentration or alertness. Make sure these abilities are not affected before you drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Mirzagen tablets exactly as your doctor or pharmacist tells you to. You should check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take</strong></p><p><strong>The usual starting dose is 15 or 30 mg every day</strong>.&nbsp;Your doctor may advise you to increase your dose after a few days to the amount that is best for you (between 15 and 45 mg per day). The dose is usually the same for all ages. However, if you are an elderly person or if you have renal or liver disease, your doctor may adapt the dose.</p><p><strong>When to take Mirzagen tablets</strong></p><p>Take Mirzagen tablets at the same time each day.</p><p>It is best to take Mirzagen tablets as a single dose before you go to bed. However your doctor may suggest splitting your dose of Mirzagen tablets - once in the morning and once at night-time before you go to bed. The higher dose should be taken before you go to bed.</p><p>Take your tablets orally. Swallow your prescribed dose of Mirzagen tablets without chewing, with some water or juice.</p><p><strong>When can you expect to start feeling better</strong></p><p>Usually Mirzagen tablets will start working after 1 to 2 weeks and after 2 to 4 weeks you may start to feel better.</p><p>It is important that, during the first few weeks of the treatment, you talk with your doctor about the effects of Mirzagen tablets:</p><p>2 to 4 weeks after you have started taking Mirzagen tablets, talk to your doctor about how this medicine has affected you.</p><p>If you still don&#39;t feel better, your doctor may prescribe a higher dose. In that case, talk to your doctor again after another 2 to 4 weeks. Usually you will need to take Mirzagen tablets until your symptoms of depression have disappeared for 4 to 6 months.</p><p><strong>If you take more Mirzagen tablets than you should</strong></p><p>If you or someone else have taken too much Mirzagen tablets, call a doctor straight away.</p><p>The most likely signs of an overdose of Mirzagen tablets (without other medicines or alcohol) are&nbsp;drowsiness, disorientation and increased heart rate.</p><p><strong>If you forget to take Mirzagen tablets</strong></p><p>If you are supposed to take your dose&nbsp;once a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have forgotten to take your dose of Mirzagen tablets, do not take the missed dose. Just skip it. Take your next dose at the normal time.</p><p>If you are supposed to take your dose&nbsp;twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have forgotten to take your morning dose, simply take it together with your evening dose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have forgotten to take your evening dose, do not take it with the next morning dose; just skip it and continue with your normal morning and evening doses</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have forgotten to take both doses, do not attempt to make up for the missed doses. Skip both doses and continue the next day with your normal morning and evening doses.</p><p><strong>If you stop taking Mirzagen tablets</strong></p><p>Only stop taking Mirzagen tablets in consultation with your doctor.</p><p>If you stop too early, your depression might come back. Once you are feeling better, talk to your doctor. Your doctor will decide when treatment can be stopped.</p><p>Do not suddenly stop taking Mirzagen tablets, even when your depression has lifted. If you suddenly stop taking Mirzagen tablets you may feel sick, dizzy, agitated or anxious, and have headaches. These symptoms can be avoided by stopping gradually. Your doctor will tell you how to decrease the dose gradually.</p><p>If you have any further questions on the use of this product ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Mirzagen tablets can cause side effects, although not everybody gets these side effects.</p><p>Some side effects are more likely to occur than others. The possible side effects of Mirzagen are listed below and can be divided as:</p><p><strong>Very common</strong>: affects more than 1 user in 10</p><p><strong>Common</strong>: affects 1 to 10 users in 100</p><p><strong>Uncommon</strong>: affects 1 to 10 users in 1,000</p><p><strong>Rare</strong>: affects 1 to 10 users in 10,000</p><p><strong>Very rare</strong>: affects less than 1 user in 10,000</p><p><strong>Not known</strong>: cannot be estimated from the available data</p><p><strong>Very common:</strong></p><ul><li>Increase in appetite and weight gain</li><li>Drowsiness or sleepiness</li><li>Headache</li><li>Dry mouth</li></ul><p><strong>Common:</strong></p><ul><li>Lethargy</li><li>Dizziness</li><li>Shakiness or tremor</li><li>Nausea</li><li>Diarrhoea</li><li>Constipation</li><li>Vomiting</li><li>Rash or skin eruptions (exanthema)</li><li>Pain in your joints (arthralgia) or muscles (myalgia)</li><li>Back pain</li><li>Feeling dizzy or faint when you stand up suddenly (orthostatic hypotension)</li><li>Swelling (typically in ankles or feet) caused by fluid retention (oedema)</li><li>Tiredness</li><li>Vivid dreams</li><li>Confusion</li><li>Feeling anxious</li><li>Sleeping problems</li><li>Memory problems, which in most cases resolved when treatment was stopped.</li></ul><p><strong>Uncommon:</strong></p><ul><li>Feeling elated or emotionally &#39;high&#39; (mania) Stop taking Mirzagen and tell your doctor straight away.</li><li>Abnormal sensation in the skin e.g. burning, stinging, tickling or tingling (paraesthesia)</li><li>Restless legs</li><li>Fainting (syncope)</li><li>Sensations of numbness in the mouth (oral hypoaesthesia)</li><li>Low blood pressure</li><li>Nightmares</li><li>Feeling agitated</li><li>Hallucinations</li><li>Urge to move</li></ul><p><strong>Rare:</strong></p><ul><li>Yellow colouring of eyes or skin: this may suggest disturbance in liver function (jaundice)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Stop taking Mirzagen and tell your doctor straight away.</li><li>Muscle twitching or contractions (myoclonus) .</li><li>Pancreatitis .</li></ul><p><strong>Not known:</strong>&nbsp;</p><ul><li>Increased salivation.</li><li>Sleepwalking.</li><li>Impaired speech.</li><li>Signs of infection such as sudden unexplainable high fever, sore throat and mouth ulcers (agranulocytosis), Stop taking Mirzagen and contact your doctor straight away for a blood test.</li><li>In rare cases, Mirzagen can cause disturbances in the production of blood cells (bone marrow depression).</li><li>Some people become less resistant to infection because Mirzagen can cause a temporary shortage of white blood cells (granulocytopenia).</li><li>In rare cases, Mirzagen can also cause a shortage of red and white blood cells, as well as blood platelets (aplastic anaemia), a shortage of blood platelets (thrombocytopenia) or an increase in the number of white blood cells (eosinophilia) .</li><li>Epileptic attack (convulsions), Stop taking Mirzagen and tell your doctor straight away .</li><li>A combination of symptoms such as inexplicable fever, sweating, increased heart rate, diarrhea, (uncontrollable) muscle contractions, shivering, overactive reflexes, restlessness, mood changes and unconsciousness. In very rare cases, these can be signs of serotonin syndrome. Stop taking Mirzagen and tell your doctor straight away&nbsp;</li><li>Thoughts of harming or killing yourself; Contact your doctor or go to a hospital straight away</li><li>Abnormal sensations in the mouth (oral paraesthesia)</li><li>Swelling in the mouth (mouth oedema)</li><li>Severe rashes that may involve blistering and peeling of the skin (Stevens-Johnson syndrome)</li><li>Blistering or scaling decay of the skin.</li><li>Blistering rash</li><li>Round red patches on the skin.</li><li>Hyponatremia.</li><li>Inappropriate anti-diuretic hormone secretion.</li><li>Increased creatinine Kinase blood levels .</li><li>Difficulty in passing urine (Urinary retention) .</li><li>Abnormal muscle breakdown muscle pain , stiffness and/or weakness , darkening or discolouration of the urine (rhabdomyolysis) .</li><li>Swelling throughout the body (generalized oedema) .</li><li>Localized swelling .</li></ul><p>Stop using Mirzagen and contact your doctor or seek medical attention immediately if you develop one of the following serious side effects:</p><p><strong>Frequency not known:</strong></p><ul><li>Reddish patches on the trunk which are target-like macules or circular, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).</li><li>Widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome). &nbsp;</li></ul><p><strong>If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30 &deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package to protect from light &amp; moisture.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Mirzagen tablets after the expiry date, which is stated on the carton. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Mirzagen tablets contain:</strong></p><p>The active ingredient in Mirzagen is each film coated tablet contains Mirtazapine (USP) 30 mg</p><p>Other ingredients: Lactose Anhydrous, Maize Starch, Colloidal Anhydrous Silica, Low Substituted HPC, Magnesium Stearate and coating material: (Opadry yellow for 15 mg), (Opadry Buff for 30 mg) and (Opadry White for 45 mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Mirzagen tablets look like & contents of the pack

Mirzagen 30 mg tablets: Light brown colored, round, biconvex, film coated tablets with “MC13” on one side and break line on other side.

Pack size: 
Pack of Mirzagen 15 mg, 30 mg & 45 mg tablets contains 30 film coated tablets: 3 white blisters (PVC/PVDC/Alu), each blister contains 10 film coated tablets.
Hospital packs of Mirzagen 15 mg, 30 mg or 45 mg film coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong><br />Medical and Cosmetic Products Company Ltd.<br />(Riyadh Pharma)<br />P.O.Box 442, Riyadh 11411<br />Fax: +966 11 265 0505<br />Email: contact@riyadhpharma.com<br />For any information about this medicinal product, please contact the local representative of marketing<br />authorisation holder:<br />Saudi Arabia<br />Marketing department<br />Riyadh<br />Tel: +966 11 265 0111<br />Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                8/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ميرزاجن هو واحد من مجموعة من الأدوية تسمى مضادات الاكتئاب.<br />تستخدم أقراص ميرزاجن لعلاج مرض الاكتئاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL"><strong>الانتحار ومضادات الاكتئاب</strong></p><p dir="RTL">في دراسات على المدى القصير زادت مضادات الاكتئاب الخطر من التفكير والسلوك الانتحاري (الانتحار) مقارنة مع الدواء الوهمي في الاطفال والمراهقين والشباب من اضطرابات الاكتئاب الكبرى (MDD) واضطرابات نفسية اخرى. اي شخص يفكر في استخدام ميرزاجن (ميرتازابين) أقراص أو أي من مضادات الاكتئاب الأخرى في الاطفال والمراهقين أو الشباب البالغين يجب تحقيق التوازن بين المخاطر والحاجة السريرية. الدراسات قصيرة الأمد لم تظهر زيادة في خطر الانتحار مع مضادات الاكتئاب مقارنة مع الدواء الوهمي في البالغين بعد سن 24 عاما. كان هناك انخفاض في هذا الخطر مع مضادات الاكتئاب مقارنة مع الدواء الوهمي في البالغين الذين تتراوح اعمارهم بين 65 عاما أو أكثر. الاكتئاب وبعض الاضطرابات النفسية الاخرى هي في حد ذاتها مرتبطة بزيادة في خطر الانتحار. يجب مراقبة المرضى من جميع الأعمار الذين بدأوا في العلاج بمضادات الاكتئاب بشكل مناسب ورصد دقيق لأي تفاقم سريري، سلوك انتحاري، أو تغييرات غير عادية في السلوك. ينبغي نصح الأسر ومقدمي الرعاية للحاجة الى الملاحظة عن كثب والتواصل مع واصف الدواء. لم تتم الموافقة على ميرزاجن للاستخدام في الأطفال المرضى.</p></td></tr></tbody></table><p>&nbsp;</p><ul dir="rtl"><li>إذا كنت تعاني من حساسية (الحساسية) لميرزاجن أو لأي من المكونات الأخرى لأقراص ميرزاجن. إذا كان الأمر كذلك، يجب عليك التحدث مع طبيبك في أقرب وقت ممكن قبل تناول اقراص ميرزاجن.</li><li>إذا كنت تتناول أو تناولت مؤخرا (في حدود الأسبوعين الأخيرين) الأدوية المعروفة باسم مثبطات أوكسيديز أحادي الأمين (MAO-Is).</li><li>إذا أصبت في أي وقت مضى بطفح جلدي شديد أو تقشر جلدي ، و / أو تقرحات و / أو تقرحات في الفم بعد تناول ميرزاجن أو أي منتج (منتجات) طبية أخرى.</li></ul><p><strong>عناية خاصة مع ميرزاجن</strong></p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين تحت سن 18 سنة من العمر</strong></p><p dir="RTL">ينبغي عادة ألا تستخدم ميرزاجن للأطفال والمراهقين دون سن 18 عاما. أيضا، يجب أن تعرف أن المرضى الذين تقل أعمارهم عن 18 تزيد لديهم مخاطر الآثار الجانبية مثل محاولة الانتحار، وأفكار انتحارية والعداء (في الغالب العدوانية، وسلوك المعارضة والغضب) عندما يتناولون هذه الفئة من الأدوية. على الرغم من هذا، فإن طبيبك قد يصف ميرزاجن للمرضى تحت 18 لأنه / أنها قرر أن هذا في مصلحتهم. إذا كان طبيبك وصف ميرزاجن للمريض دون سن 18 عاما وكنت ترغب في مناقشة هذا الموضوع، يرجى الرجوع إلى الطبيب. يجب إبلاغ الطبيب إذا كان أي من الأعراض المذكورة أعلاه تتطور أو تزداد سوءا عند المرضى الذين تقل أعمارهم عن 18 ويتناولون ميرزاجن. أيضا، لم يتم حتى الآن اثبات آثار السلامة على المدى الطويل بشأن النمو والنضج والتطور المعرفي والسلوكي للميرزاجن في هذه الفئة العمرية.</p><p dir="RTL"><strong>أفكار الانتحار وتفاقم الاكتئاب الخاص بك</strong></p><p dir="RTL">إذا كنت مكتئبا يمكن أن يكون في بعض الأحيان لديك أفكار إيذاء أو قتل نفسك. هذه يمكن أن تزيد عندما بدأت لأول مرة مضادات الاكتئاب، لأن كل هذه الأدوية تستغرق وقتا للعمل تبلغ عادة نحو أسبوعين لكن في بعض الأحيان لفترة أطول.</p><p dir="RTL">قد تميل للتفكير على هذا النحو:</p><ul dir="rtl"><li>إذا كان قد سبق لديك أفكار حول قتل أو إيذاء نفسك.</li><li>إذا كنت من الشباب البالغين. قد أظهرت المعلومات المستقاة من التجارب السريرية زيادة مخاطر السلوك الانتحاري لدى البالغين الذين تقل أعمارهم عن 25 عاما يعانون من حالة نفسية و تم علاجهم بمضاد للاكتئاب.</li></ul><p dir="RTL">إذا كان لديك أفكار إيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور.</p><p dir="RTL"><strong>قد تجد أنه من المفيد إخبار قريب أو صديق موثوق به</strong> أنك مكتئبا، واطلب منهم قراءة هذه النشرة. قد تطلب منهم ان يخبروك إذا كانوا يعتقدون الاكتئاب الخاص بك يزداد سوءا، أو إذا كانوا قلقين بشأن التغيرات في سلوكك.</p><p dir="RTL"><strong>أيضاً ضع عناية خاصة مع ميرزاجن</strong></p><p>- إذا كان لديك، أو كان لديك في أي وقت مضى إحدى الحالات التالية. أخبر طبيبك عن هذه الحالات قبل تناول ميرزاجن، إذا لم تكن قد فعلت من قبل.</p><ul dir="rtl"><li><strong>نوبات</strong> (الصرع). إذا تطورت النوبات أو أصبحت النوبات الخاصة بك أكثر تواترا، توقف عن تناول ميرزاجن واتصل بطبيبك فورا؛</li><li><strong>أمراض الكبد</strong>، بما في ذلك اليرقان. في حال حدوث اليرقان، توقف عن تناول ميرزاجن واتصل بطبيبك فورا؛</li><li><strong>أمراض الكلى</strong>.</li><li><strong>أمراض القلب</strong>، أو انخفاض ضغط الدم.</li><li><strong>الفصام</strong>. إذا أصبحت الأعراض الذهانية، مثل الأفكار بجنون العظمة أكثر تواترا أو شدة، اتصل بطبيبك على الفور.</li><li><strong>الإ</strong><strong>كتئاب الهوسي</strong> (التناوب بفترات الشعور بالابتهاج / فرط نشاط وفترات المزاج المكتئب). إذا بدأت الشعور بالغبطة أو الإفراط في الإثارة توقف عن تناول ميرزاجن واتصل بطبيبك فورا؛</li><li><strong>مرض السكري</strong> (قد تحتاج لتعديل جرعتك من الأنسولين أو الأدوية المضادة لمرض السكر الأخرى)؛</li><li><strong>أمراض العين</strong>، مثل زيادة الضغط في العين (الجلوكوما)؛</li><li><strong>صعوبة في التبول</strong>، والتي قد تكون ناجمة عن تضخم البروستاتا.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهر عليك علامات العدوى مثل ارتفاع درجة الحرارة غير المبرر، والتهاب الحلق وتقرحات الفم.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف عن تناول ميرزاجن واستشر الطبيب فورا لإجراء اختبار الدم. في حالات نادرة هذه الأعراض يمكن أن تكون علامات لاضطرابات في إنتاج خلايا الدم في نخاع العظام. بينما نادرة، وهذه الأعراض تظهر غالبا بعد 4-6 أسابيع من العلاج.</p><p dir="RTL">-&nbsp;إذا كنت شخص مسن فقد تكون أكثر حساسية لالآثار الجانبية من مضادات الاكتئاب</p><p dir="RTL">- الحالات التي تحتاج إلى إشراف مثل اضطرابات الغدد الصماء: فرط برولاكتين الدم (والأعراض ذات الصلة، مثل اضطراب ادرار اللبن والتثدي).</p><p dir="RTL">- تم الإبلاغ عن تفاعلات جلدية خطيرة بما في ذلك متلازمة ستيفنز جونسون (SJS) ، وانحلال البشرة السمي TEN) &nbsp;) والتفاعل الدوائي مع فرط الحمضات والأعراض الجهازية&nbsp; (DRESS)&nbsp; مع استخدام ميرزاجن. توقف عن الاستخدام واطلب العناية الطبية فورًا إذا لاحظت أيًا منها من الأعراض الموصوفة في القسم 4 فيما يتعلق بتفاعلات الجلد الخطيرة. إذا كنت قد أصبت في أي وقت مضى بأي تفاعلات جلدية شديدة ، فلا ينبغي إعادة العلاج باستخدام ميرزاجن.</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول (أو تخطط لتناول) أي من الأدوية في القائمة التالية:</p><p dir="RTL">من فضلك أخبر أيضا طبيبك أو الصيدلي إذا كنت تأخذ أو اتخذت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL"><strong>لا تتناول ميرزاجن بالاشتراك مع:</strong></p><ul dir="rtl"><li>مثبطات أوكسيديز أحادي الأمين (مثبطات MAO). أيضا، لا تتناول ميرزاجن خلال أسبوعين بعد أن كنت قد توقفت عن تناول مثبطات MAO. إذا توقفت عن تناول ميرزاجن، لا تتناول مثبطات MAO خلال الأسبوعين القادمين أيضا.</li></ul><p dir="RTL">ومن الأمثلة على مثبطات MAO هي موكلوبميد، ترانيلسيبرومين (كلاهما من مضادات الاكتئاب) وسيليجيلين (الذي يستخدم لمرض الشلل الرعاش).</p><p dir="RTL"><strong>عناية خاصة</strong> عند تناول ميرزاجن بالاشتراك مع:</p><ul dir="rtl"><li>مضادات الاكتئاب مثل SSRls، الفينلافاكسين و-L تريبتوفان، أو أدوية التريبتان (التي تستخدم لعلاج الصداع النصفي)، ترامادول (قاتل للألم)، لينيزوليد (مضاد حيوي)، والليثيوم (الذي يستخدم لعلاج بعض الحالات النفسية) ونبتة سانت جون - مستحضرات بيرفوراتوم (علاج بالاعشاب لعلاج الاكتئاب). في حالات نادرة جدا ميرزاجن وحده أو بالاشتراك من ميرزاجن مع هذه الأدوية، يمكن أن يؤدي إلى ما يسمى بمتلازمة السيروتونين. بعض من أعراض هذه المتلازمة هي: الحمى غير المبررة، والتعرق، وزيادة معدل ضربات القلب والإسهال وتقلصات (لا يمكن السيطرة عليها) في العضلات ورجفة، وردود فعل فرط النشاط، والأرق، وتغيرات في المزاج، وفقدان الوعي. إذا كنت تحصل على مزيج من هذه الأعراض، تحدث الى الطبيب فورا.</li><li>مضاد الاكتئاب نيفازودون. يمكن أن تزيد من كمية ميرزاجن في دمك. ابلغ طبيبك إذا كنت تستخدم هذا الدواء. قد تكون هناك حاجة لخفض جرعة من ميرزاجن، أو عند إيقاف استخدام نيفازودون، لزيادة الجرعة من ميرزاجن مرة أخرى.</li><li><strong>أدوية القلق أو الأرق</strong> مثل البنزوديازيبينات.</li><li><strong>أدوية الفصام</strong> مثل الأولانزابين.</li><li><strong>أدوية الحساسية</strong> مثل السيتريزين.</li><li><strong>أدوية الألم الشديد</strong> مثل المورفين.</li></ul><p dir="RTL">بالاشتراك مع هذه الأدوية يمكن أن يزيد ميرزاجن من النعاس الذي تسببه هذه الأدوية.</p><ul dir="rtl"><li><strong>أدوية العدوى</strong>: أدوية للالتهابات البكتيرية (مثل الاريثروميسين)؛ أدوية للالتهابات الفطرية (مثل الكيتوكونازول) وأدوية فيروس نقص المناعة البشرية / الإيدز (مثل مثبطات الأنزيم البروتيني HIV).</li></ul><p dir="RTL">بالاشتراك مع ميرزاجن هذه الأدوية يمكن أن تزيد من كمية ميرزاجن في دمك. ابلغ طبيبك إذا كنت تستخدم هذه الأدوية. قد تكون هناك حاجة لخفض جرعة ميرزاجن، أو عندما يتم إيقاف هذه الأدوية، يتم زيادة جرعة ميرزاجن مرة أخرى.</p><ul dir="rtl"><li><strong>أدوية الصرع</strong> مثل كاربامازيبين والفينيتوين.</li><li><strong>أدوية السل</strong> مثل ريفامبيسين.</li></ul><p dir="RTL">بالاشتراك مع ميرزاجن هذه الأدوية يمكن أن تقلل من كمية ميرزاجن في دمك. أبلغ طبيبك إذا كنت تستخدم هذه الأدوية. قد تكون هناك حاجة إلى أن تزيد جرعة ميرزاجن، أو عندما يتم إيقاف هذه الأدوية، يتم خفض جرعة ميرزاجن مرة أخرى.</p><ul dir="rtl"><li><strong>أدوية لمنع تخثر الدم</strong> مثل الوارفارين.</li></ul><p dir="RTL">ميرزاجن يمكن أن تزيد من تأثير الوارفارين على الدم. إبلغ الطبيب إذا كنت تستخدم هذا الدواء. في حالة الجمع ينصح الطبيب بأن يراقب الدم بعناية.</p><ul dir="rtl"><li><strong>الأدوية التي قد تؤثر على إيقاع القلب</strong> مثل بعض المضادات الحيوية وبعض مضادات الذهان.</li></ul><p dir="RTL"><strong>تناول أقراص ميرزاجن مع الطعام والشراب</strong></p><p dir="RTL">ينصح عدم شرب أي نوع من الكحول.</p><p dir="RTL">قد يحدث لك النعاس إذا كنت تشرب الكحول أثناء تناول ميرزاجن.</p><p dir="RTL">يمكنك أن تتناول أقراص ميرزاجن مع أو بدون الطعام.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL">تجربة محدودة مع تناول ميرزاجن للنساء الحوامل لا تشير إلى وجود خطر متزايد. ومع ذلك، ينبغي توخي الحذر عند استخدامه خلال فترة الحمل.</p><p dir="RTL">إذا كنت تتناولين أقراص ميرزاجن وأصبحت حاملا أو تخططين للحمل، اسألي طبيبك عما إذا كنتي قد تستمرين بتناول اقراص ميرزاجن. إذا كنت تستخدمين أقراص ميرزاجن حتى، أو قبل وقت قصير من الولادة، يجب أن يكون طفلك تحت الإشراف والمتابعة للآثار السلبية المحتملة.</p><p dir="RTL">اسألي طبيبك ما إذا كان يمكنك الرضاعة الطبيعية أثناء تناول اقراص ميرزاجن.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن لأقراص ميرزاجن أن تؤثر على القدرة على التركيز أو اليقظة. تأكد ألا تتأثر هذه القدرات قبل القيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائما أقراص ميرزاجن تماما كما أخبرك طبيبك أو الصيدلي. يجب عليك التحقق مع طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL"><strong>كم يجب أن تتناول</strong></p><p dir="RTL">جرعة البداية المعتادة هي 15 أو 30 ملجم يوميا. طبيبك قد ينصحك لزيادة الجرعة بعد بضعة أيام إلى المقدار الأفضل لك (ما بين 15 و 45 ملجم يوميا). الجرعة عادة ما تكون هي نفسها لجميع الأعمار. ومع ذلك، إذا كنت شخص مسن أو إذا كان لديك مرض الكلى أو الكبد، فإن طبيبك قد يكيف الجرعة.</p><p dir="RTL"><strong>متى تتناول أقراص ميرزاجن</strong></p><p dir="RTL">تناول أقراص ميرزاجن في نفس الوقت كل يوم.</p><p dir="RTL">فمن الأفضل أن تتناول أقراص ميرزاجن كجرعة واحدة قبل أن تذهب إلى النوم. ومع ذلك قد يقترح الطبيب تقسيم الجرعة من أقراص ميرزاجن - مرة واحدة في الصباح ومرة في الليل قبل الذهاب إلى النوم. وينبغي أن تتناول الجرعة الأعلى قبل أن تذهب إلى النوم.</p><p dir="RTL">تناول الأقراص الخاصة بك عن طريق الفم. ابتلع الجرعة المقررة من أقراص ميرزاجن دون مضغ، مع بعض الماء أو العصير.</p><p dir="RTL"><strong>متى يمكنك أن تتوقع بداية الشعور بتحسن</strong></p><p dir="RTL">عادة ما تبدأ أقراص ميرزاجن العمل بعد 1-2 أسابيع وبعد 2 إلى 4 أسابيع قد تبدأ في الشعور بتحسن.</p><p dir="RTL">ومن المهم أنه خلال الأسابيع القليلة الأولى من العلاج أن تتحدث مع طبيبك حول تأثير اقراص ميرزاجن:</p><p dir="RTL">بعد 2 إلى 4 أسابيع من بداية تناولك لأقراص ميرزاجن، تحدث مع طبيبك حول كيفية تأثير هذا الدواء عليك.</p><p dir="RTL">إذا كنت لا تزال لا تشعر بتحسن، فإن طبيبك قد يصف جرعة أعلى. في هذه الحالة، تحدث الى الطبيب مرة أخرى بعد 2 إلى 4 أسابيع أخرى. وعادة ما سوف تحتاج إلى تناول أقراص ميرزاجن حتى تختفي أعراض الاكتئاب لمدة 4 إلى 6 أشهر.</p><p dir="RTL"><strong>إذا تناولت أقراص ميرزاجن أكثر مما يجب</strong></p><p dir="RTL">إذا كنت أنت أو شخص آخر قد تناولت الكثير من أقراص ميرزاجن، إستدعى الطبيب على الفور.</p><p dir="RTL">علامات الجرعة الزائدة من أقراص ميرزاجن على الأرجح (بدون الأدوية أو الكحول الأخرى) هي النعاس، التوهان وزيادة معدل ضربات القلب.</p><p dir="RTL"><strong>إذا نسيت أن تتناول أقراص ميرزاجن</strong></p><p dir="RTL">إذا كان من المفترض أن تتناول الجرعة مرة واحدة يوميا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تناول جرعة من أقراص ميرزاجن، لا تأخذ الجرعة المنسية. تخطاها. خذ الجرعة التالية في الوقت العادي.</p><p dir="RTL">إذا كان من المفترض أن تتناول الجرعة مرتين في اليوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت أن تتناول جرعة الصباح الخاص بك، ببساطة تناولها جنبا إلى جنب مع جرعة المساء الخاص بك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تناول جرعة المساء، لا تتناولها مع جرعة صباح اليوم التالي. تخطاها وتواصل مع الجرعات العادية بالصباح والمساء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تناول كلا الجرعتين، لا تحاول التعويض عن الجرعات المنسية. تخطي كلا الجرعتين واستمر في اليوم التالي مع الجرعات العادية بالصباح والمساء</p><p dir="RTL"><strong>إذا توقفت عن أخذ أقراص ميرزاجن</strong></p><p dir="RTL">يتوقف تناول اقراص ميرزاجن فقط بالتشاور مع طبيبك.</p><p dir="RTL">إذا توقفت في وقت مبكر جدا، فالاكتئاب قد يعود لك. بمجرد شعورك بتحسن تحدث الى الطبيب. طبيبك سوف يقرر متى يمكن إيقاف العلاج.</p><p dir="RTL">لا تتوقف فجأة عن تناول اقراص ميرزاجن، حتى عندما يخف الاكتئاب الخاص بك. إذا توقفت فجأة عن تناول اقراص ميرزاجن قد تشعر باعتلال، ودوار، وهياج أو بالقلق، وتشعر بالصداع. ويمكن تجنب هذه الأعراض عن طريق الإيقاف التدريجي. طبيبك سيخبرك عن كيفية تقليل الجرعة تدريجيا.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج إسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية أقراص ميرزاجن يمكن أن تتسبب في آثار جانبية، وإن لم يكن كل شخص تحدث له هذه الآثار الجانبية.</p><p dir="RTL">بعض الآثار الجانبية من المرجح أن تحدث عن غيرها. سرد الآثار الجانبية المحتملة لميرزاجن أدناه، ويمكن تقسيمها على النحو التالي:</p><p dir="RTL"><strong>شائع جدا</strong>: يؤثر على أكثر من 1 مستخدم من كل 10 مستخدمين</p><p dir="RTL"><strong>شائع</strong>: يؤثر على 1 إلى 10 مستخدمين من كل 100 مستخدم</p><p dir="RTL"><strong>غير شائع</strong>: يؤثر على 1 إلى 10 مستخدمين من كل 1000 مستخدم</p><p dir="RTL"><strong>نادر</strong>: يؤثر على 1 إلى 10 مستخدمين من كل 10،000 مستخدم</p><p dir="RTL"><strong>نادرة جدا</strong>: يؤثر على أقل من 1 مستخدم من كل 10000 مستخدم</p><p dir="RTL"><strong>غير معروف</strong>: لا يمكن تقديرها من البيانات المتاحة</p><p dir="RTL"><strong>شائع جدا:</strong></p><ul dir="rtl"><li>زيادة في الشهية وزيادة الوزن</li><li>الخمول أو النعاس</li><li>الصداع</li><li>جفاف الفم</li></ul><p dir="RTL"><strong>شائعة:</strong></p><ul dir="rtl"><li>الخمول</li><li>دوخة</li><li>الاهتزاز أو الارتجاف</li><li>الغثيان</li><li>الإسهال</li><li>الإمساك</li><li>القيء</li><li>طفح الجلد أو ثورات (طفح)</li><li>ألم في المفاصل (آلام المفاصل) أو العضلات (آلام العضلات)</li><li>آلام الظهر</li><li>الشعور بالدوار أو الإغماء عند الوقوف فجأة (انخفاض ضغط الدم القيامي)</li><li>تورم (عادة في الكاحلين أو القدمين) بسبب احتباس السوائل (وذمة)</li><li>التعب</li><li>أحلام يقظة</li><li>الارتباك</li><li>الشعور بالقلق</li><li>مشاكل النوم</li><li>مشاكل الذاكرة ، والتي يتم حلها في معظم الحالات عند توقف العلاج.</li></ul><p dir="RTL"><strong>غير شائعة:</strong></p><ul dir="rtl"><li>الشعور بالابتهاج والفرحة العارمة (النشوة) توقف عن تناول ميرزاجن وأخبر طبيبك على الفور.</li><li>إحساس غير طبيعي في الجلد مثلا حرقان، اللسع، دغدغة أو وخز (تنميل أو نخر)</li><li>تململ الساقين</li><li>الإغماء (الغشيان)</li><li>أحساس بالتخدر في الفم (نقص الحس عن طريق الفم)</li><li>انخفاض ضغط الدم</li><li>الكوابيس</li><li>الشعور بالهياج</li><li>الهلوسة</li><li>الالحاح على التحرك</li></ul><p dir="RTL"><strong>نادر:</strong></p><ul dir="rtl"><li>تلون العينين أو الجلد باللون الأصفر: هذا قد يوحي باضطراب في وظيفة الكبد (اليرقان)</li></ul><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; توقف عن تناول ميرزاجن وأخبر طبيبك على الفور.</p><ul dir="rtl"><li>ارتعاش العضلات أو تقلصات (رمع عضلي)</li><li>التهاب البنكرياس.</li></ul><p dir="RTL"><strong>غير معروف&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><ul dir="rtl"><li>زيادة إفراز اللعاب.</li><li>المشي أثناء النوم.</li><li>اضطراب الكلام (عسر التلفظ).</li><li>علامات العدوى، مثل ارتفاع درجة الحرارة المفاجئ (الغير مفسر)، والتهاب الحلق وتقرحات الفم (ندرة المحببات)، توقف عن تناول ميرزاجن واتصل بطبيبك على الفور لفحص الدم.</li><li>في حالات نادرة، يمكن أن يسبب ميرزاجن اضطرابات في إنتاج خلايا الدم (نقص في نخاع العظام).</li><li>بعض الناس يصبحون أقل مقاومة للعدوى بسبب ميرزاجن، حيث انه يمكن أن يسبب نقص مؤقت من خلايا الدم البيضاء (المحببات).</li><li>في حالات نادرة، ميرزاجن يمكن أيضا أن يسبب نقص خلايا الدم الحمراء والبيضاء، وكذلك الصفائح الدموية (فقر الدم اللاتنسجي)، أو زيادة في عدد خلايا الدم البيضاء (فرط الحمضات)</li><li>نوبات الصرع (التشنجات)، توقف عن تناول ميرزاجن&nbsp;وأخبر طبيبك على الفور.</li><li>مجموعة من الأعراض مثل الحمى (الغير مفسره)، والتعرق، وزيادة معدل ضربات القلب والإسهال وتقلصات (لا يمكن السيطرة عليها) في العضلات، الرعشة، فرط النشاط، والأرق، وتغيرات في المزاج وفقدان الوعي. في حالات نادرة جدا، يمكن أن تكون هذه علامات متلازمة السيروتونين. توقف عن تناول ميرزاجن وأخبر الطبيب على الفور.</li><li>خواطر بإيذاء النفس أو الانتحار. اتصل بطبيبك أو اذهب إلى المستشفى على الفور</li><li>أحاسيس غير طبيعية في الفم (تنميل بالفم)</li><li>تورم في الفم (وذمة الفم)</li><li>الطفح الجلدي الحاد والذي قد يشمل تقرح وتقشير للجلد (متلازمة ستيفنز جونسون)</li><li>التقرح أو زيادة انحلال الجلد.</li><li>طفح تقرحي للجلد.</li><li>بقع حمراء مستديرة على الجلد</li><li>نقص صوديوم الدم</li><li>إفراز غير مناسب للهرمون مانع ادرار البول</li><li>زيادة مستويات انزيم الكرياتينين كينيز في الدم.</li><li>صعوبة اخراج البول (احتباس البول).</li><li>انهيار غير طبيعي للعضلات ، ألم في العضلات، تصلب و / أو ضعف، سواد أو تغيير لون البول (رابدوميوليسيس). تورم في جميع أنحاء الجسم (وذمة عامة).</li><li>تورم موضعي.</li></ul><p dir="RTL">توقف عن استخدام&nbsp; ميرزاجن واتصل بطبيبك أو اطلب العناية الطبية على الفور إذا ظهرت لديك أحد الآثار الجانبية الخطيرة التالية:</p><p dir="RTL"><strong>التكرار غير معروف</strong><strong>:</strong></p><ul><li dir="RTL">بقع حمراء على الجذع دائرية أو تشبه اللطخات ، غالبًا مع ظهور بثور مركزية ، وتقشير الجلد ، وتقرحات في الفم والحلق والأنف والأعضاء التناسلية والعينين. يمكن أن تسبق هذه الطفح الجلدي الشديد الحمى وأعراض تشبه أعراض الأنفلونزا (متلازمة ستيفنز جونسون ، انحلال البشرة النخري السمي).</li><li dir="RTL">انتشار الطفح الجلدي وارتفاع درجة حرارة الجسم وتضخم الغدد الليمفاوية (متلازمة دريس أو متلازمة فرط الحساسية للأدوية).</li></ul><p dir="RTL"><strong>إذا اصبح أي من الآثار الجانبية خطير أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة رجاءً أخبر طبيبك أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول ونظر الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في العبوة الأصلية للحماية من الضوء والرطوبة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم أقراص ميرزاجن بعد تاريخ انتهاء الصلاحية المذكور على الكرتون. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن لا يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية لم تعد مطلوبة. سوف تساعد هذه التدابير&nbsp; &nbsp;لحماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة في ميرزاجن هي ميرتازابين يحتوي كل قرص مغلف على ميرتازابين (دستور الأدوية الأمريكي) 30 ملجم</p><p>المواد الإضافية: لاكتوز لامائي، نشا ذرة، كولويدال سيليكا لامائي، لوو سبستيتيوتد HPC، مجنيسيوم ستياريت ومادة مغلفة: (أوبادري أصفر لتركيز 15 ملجم)، (أوبادري باف لتركيز 30 ملجم) و(أوبادري أبيض لتركيز 45 ملجم).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يبدو </strong><strong>ميرزاجن</strong><strong> وماهي محتويات العبوة</strong></p><p>ميرزاجن 30 ملجم أقراص: أقراص مغلفة لونها بني باهت، مستديرة، محدبة الطرفين، مطبوع على أحد اوجهها &quot; &ldquo;MC13 وبها خط للتقسيم على الوجه الأخر.</p><p><strong>حجم العبوة</strong></p><p>&nbsp;كل عبوة من ميرزاجن 15 ملجم، 30 ملجم أو 45 ملجم تحتوي على 30 قرص: 3 أشرطة (PVC/PVDC/Alu) بكل منها 10 أقراص.</p><p>عبوات مستشفيات تحتوي على أقراص مغلفة من ميرزاجن 15 ملجم، 30 ملجم أو45 ملجم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة المنتجات الطبية والتجميلية المحدودة ( الرياض فارما)</p><p>ص.ب. 442 الرياض 11411</p><p>فاكس: 966112650505+</p><p>البريد الإلكتروني: contact@riyadhpharma.com</p><p><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على&nbsp; صاحب الترخيص والتسويق:</em></p><p>المملكة العربية السعودية</p><p>قسم التسويق</p><p>الرياض</p><p>تلفون: 966112650111+</p><p>البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            08/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MIRZAGEN 30mg FILM COATED TABLETS
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mirzagen 30 mg tablets Light brown colored, round, biconvex, film coated tablets with “MC13” on one side and break line on other side.

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>Treatment of episodes of major depression.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p><u>Posology</u></p><p><em>Adults</em></p><p>The effective daily dose is usually between 15mg and 45mg; the starting dose is 15mg or 30mg. Mirtazapine begins to exert its effect in general after 1-2 weeks of treatment. Treatment with an adequate dose should result in a positive response within 2-4 weeks. With an insufficient response, the dose can be increased up to the maximum dose. If there is no response within a further 2-4 weeks, then treatment should be stopped.</p><p>Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms.</p><p>It is recommended to discontinue treatment with mirtazapine gradually to avoid withdrawal symptoms (see section 4.4).</p><p><em>Elderly</em></p><p>The recommended dose is the same as that for adults. In elderly patients an increase in dosing should be done under close supervision to elicit a satisfactory and safe response.</p><p><em>Renal impairment</em></p><p>The clearance of mirtazapine may be decreased in patients with moderate to severe renal impairment (creatinine clearance &lt;40 ml/min). This should be taken into account when prescribing Mirtazapine tablets to this category of patients (see section 4.4).</p><p><em>Hepatic impairment</em></p><p>The clearance of mirtazapine may be decreased in patients with hepatic impairment. This should be taken into account when prescribing Mirtazapine tablets to this category of patients, particularly with severe hepatic impairment, as patients with severe hepatic impairment have not been investigated (see section 4.4).</p><p><em>Paediatric population</em></p><p>Mirtazapine tablets should not be used in children and adolescents under the age of 18 years (see section 4.4) as efficacy was not demonstrated in two short-term clinical trials (see section 5.1) and because of safety concerns (see sections 4.4, 4.8 and 5.1).</p><p><u>Method of administration</u></p><p>Mirtazapine has an elimination half-life of 20-40 hours and therefore Mirtazapine tablets are suitable for once daily administration. It should be taken preferably as a single night-time dose before going to bed. Mirtazapine tablets may also be given in two divided doses (once in the morning and once at night-time, the higher dose should be taken at night).</p><p>The tablets should be taken orally, with fluid, and swallowed without chewing.</p></td><td><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
Concomitant use of mirtazapine with monoamine oxidase (MAO) inhibitors (see section 4.5).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>&ldquo;Suicidality and Antidepressant Drugs</p><p>Antidepressants increased the risk compared to placebo of suicidal thinking and behaviour (suicidality) in children, adolescents, and young adults in short term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of MIRZAGEN (mirtazapine) Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behaviour. Families and caregivers should be advised of the need for close observation and communication with the prescriber. MIRZAGEN is not approved for use in paediatric patients. (See 4.4 Special warnings and precautions for use)&rdquo;</p></td></tr></tbody></table><p><u>Severe cutaneous adverse reactions </u></p><p>Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), bullous dermatitis and erythema multiforme, which can be life-threatening or fatal, have been reported in association with Mirzagen treatment.</p><p>If signs and symptoms suggestive of these reactions appear, Mirzagen should be withdrawn immediately.</p><p>If the patient has developed one of these reactions with the use of Mirzagen , treatment with Mirzagen must not be restarted in this patient at any time.</p><p><u>Paediatric population</u></p><p>Mirzagen should not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In, addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p><u>Suicide/suicidal thoughts or clinical worsening</u></p><p>Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressants in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>Close supervision of patients and in particular those at high risk should accompany therapy with antidepressants especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p>With regard to the chance of suicide, in particular at the beginning of treatment, only the smallest amount of Mirzagen orodispersible tablets should be given to the patient consistent with good patient management, in order to reduce the risk of overdose.</p><p><u>Bone marrow depression</u></p><p>Bone marrow depression, usually presenting as granulocytopenia or agranulocytosis, has been reported during treatment with Mirzagen. Reversible agranulocytosis has been reported as a rare occurrence in clinical studies with Mirzagen. In the postmarketing period with Mirzagen very rare cases of agranulocytosis have been reported, mostly reversible, but in some cases fatal. Fatal cases mostly concerned patients with an age above 65. The physician should be alert for symptoms like fever, sore throat, stomatitis or other signs of infection; when such symptoms occur, treatment should be stopped and blood counts taken.</p><p><u>Jaundice</u></p><p>Treatment should be discontinued if jaundice occurs.</p><p><u>Conditions which need supervision</u></p><p>Careful dosing as well as regular and close monitoring is necessary in patients with:</p><p>&ndash; epilepsy and organic brain syndrome: Although clinical experience indicates that epileptic seizures are rare during mirtazapine treatment, as with other antidepressants, Mirzagen should be introduced cautiously in patients who have a history of seizures. Treatment should be discontinued in any patient who develops seizures, or where there is an increase in seizure frequency.</p><p>&ndash; hepatic impairment: Following a single 15 mg oral dose of mirtazapine, the clearance of mirtazapine was approximately 35 % decreased in mild to moderate hepatically impaired patients, compared to subjects with normal hepatic function. The average plasma concentration of mirtazapine was about 55 % increased.</p><p>&ndash; renal impairment: Following a single 15 mg oral dose of mirtazapine, in patients with moderate (creatinine clearance &lt;40 ml/min) and severe (creatinine clearance &le; 10 ml/min) renal impairment the clearance of mirtazapine was about 30 % and 50 % decreased respectively, compared to normal subjects. The average plasma concentration of mirtazapine was about 55 % and 115 % increased respectively. No significant differences were found in patients with mild renal impairment (creatinine clearance &lt;80 ml/min) as compared to the control group.</p><p>&ndash; cardiac diseases like conduction disturbances, angina pectoris and recent myocardial infarction, where normal precautions should be taken and concomitant medicines carefully administered.</p><p>&ndash; low blood pressure.</p><p>&ndash; diabetes mellitus: In patients with diabetes, antidepressants may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted and close monitoring is recommended.</p><p>Like with other antidepressants, the following should be taken into account:</p><p>&ndash; Worsening of psychotic symptoms can occur when antidepressants are administered to patients with schizophrenia or other psychotic disturbances; paranoid thoughts can be intensified</p><p>&ndash; When the depressive phase of bipolar disorder is being treated, it can transform into the manic phase. Patients with a history of mania/hypomania should be closely monitored. Mirtazapine should be discontinued in any patient entering a manic phase.</p><p>&ndash; Although Mirzagen is not addictive, post-marketing experience shows that abrupt termination of treatment after long term administration may sometimes result in withdrawal symptoms. The majority of withdrawal reactions are mild and self-limiting. Among the various reported withdrawal symptoms, dizziness, agitation, anxiety, headache and nausea are the most frequently reported. Even though they have been reported as withdrawal symptoms, it should be realized that these symptoms may be related to the underlying disease. As advised in section 4.2, it is recommended to discontinue treatment with mirtazapine gradually.</p><p>&ndash; Care should be taken in patients with micturition disturbances like prostate hypertrophy and in patients with acute narrow-angle glaucoma and increased intra-ocular pressure (although there is little chance of problems with Mirzagen because of its very weak anticholinergic activity).</p><p>&ndash; Akathisia/psychomotor restlessness: The use of antidepressants have been associated with the development of akathisia, characterized by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p>&ndash; Cases of QT prolongation, Torsade de Pointes, ventricular tachycardia, and sudden death, have been reported during the post-marketing use of mirtazapine. The majotity of reports occurred in association with overdose or in patients with other risk factors for QT prolongation, including concomitant use of QTc prolonging medicines (see section 4.5 and section 4.9). Caution should be exercised when Mirzagen is prescribed in patients with known cardiovascular disease or family history of QT prolongation, and in concomitant use with other medicinal products thought to prolong the QTc interval.</p><p><u>Hyponatraemia</u></p><p>Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been reported very rarely with the use of mirtazapine. Caution should be exercised in patients at risk, such as elderly patients or patients concomitantly treated with medications known to cause hyponatraemia.</p><p><u>Serotonin syndrome</u></p><p>Interaction with serotonergic active substances: serotonin syndrome may occur when selective serotonin reuptake inhibitors (SSRIs) are used concomitantly with other serotonergic active substances (see section 4.5). Symptoms of serotonin syndrome may be hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes that include confusion, irritability and extreme agitation progressing to delirium and coma. Caution should be advised and a closer clinical monitoring is required when these active substances are combined with mirtazapine. Treatment with mirtazapine should be discontinued if such events occur and supportive symptomatic treatment initiated. From post marketing experience it appears that serotonin syndrome occurs very rarely in patients treated with Mirzagen alone (see section 4.8).</p><p><u>Endocrine disorders: </u></p><p>hyperprolactinemia (and related symptoms, e.g., galactorrhea and gynecomastia).</p><p><em><u>Elderly patients</u></em></p><p>Elderly patients are often more sensitive, especially with regard to the undesirable effects of antidepressants. During clinical research with mirtazapine, undesirable effects have not been reported more often in elderly patients than in other age groups.</p></td><td><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacodynamic&nbsp;interactions</em></p><p>&bull; Mirtazapine should not be administered concomitantly with MAO inhibitors or within two weeks after discontinuation of MAO inhibitor therapy. In the opposite way about two weeks should pass before patients treated with mirtazapine should be treated with MAO inhibitors (see section 4.3).</p><p>In addition, as with SSRIs, co-administration with other serotonergic active substances (L-tryptophan, triptans, tramadol, linezolid, methylene blue, SSRIs, venlafaxine, lithium and St. John&#39;s Wort &ndash; Hypericum perforatum &ndash; preparations) may lead to an incidence of serotonin associated effects (serotonin syndrome: see section 4.4). Caution should be advised and a closer clinical monitoring is required when these active substances are combined with mirtazapine.</p><p>&bull; Mirtazapine may increase the sedating properties of benzodiazepines and other sedatives (notably most antipsychotics, antihistamine H1 antagonists, opioids). Caution should be exercised when these medicinal products are prescribed together with mirtazapine.</p><p>&bull; Mirtazapine may increase the CNS depressant effect of alcohol. Patients should therefore be advised to avoid alcoholic beverages while taking mirtazapine. Mirtazapine dosed at 30 mg once daily caused a small but statistically significant increase in the international normalized ratio (INR) in subjects treated with warfarin. As at a higher dose of mirtazapine a more pronounced effect can not be excluded, it is advisable to monitor the INR in case of concomitant treatment of warfarin with mirtazapine.</p><p>&bull; The risk of QT prolongation and/or ventricular arrhythmias (e.g. Torsade de Pointes) may be increased with concomitant use of medicines which prolong the QTc interval (e.g. some antipsychotics and antibiotics).</p><p><em>Pharmacokinetic interactions</em></p><p>&bull; Carbamazepine and phenytoin, CYP3A4 inducers, increased mirtazapine clearance about twofold, resulting in a decrease in average plasma mirtazapine concentration of 60 % and 45 %, respectively. When carbamazepine or any other inducer of hepatic metabolism (such as rifampicin) is added to mirtazapine therapy, the mirtazapine dose may have to be increased. If treatment with such medicinal product is discontinued, it may be necessary to reduce the mirtazapine dose.</p><p>&bull; Co-administration of the potent CYP3A4 inhibitor ketoconazole increased the peak plasma levels and the AUC of mirtazapine by approximately 40% and 50% respectively.</p><p>&bull; When cimetidine (weak inhibitor of CYP1A2, CYP2D6 and CYP3A4) is administered with mirtazapine, the mean plasma concentration of mirtazapine may increase more than 50 %. Caution should be exercised and the dose may have to be decreased when co-administering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, cimetidine or nefazodone.</p><p>&bull; Interaction studies did not indicate any relevant pharmacokinetic effects on concurrent treatment of mirtazapine with paroxetine, amitriptyline, risperidone or lithium.</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p><table border="0" cellpadding="0" style="width:0px"><tbody></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Limited data of the use of mirtazapine in pregnant women do not indicate an increased risk for congenital malformations. Studies in animals have not shown any teratogenic effects of clinical relevance, however developmental toxicity has been observed (see section 5.3).</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated the association of PPHN to mirtazapine treatment, this potential risk cannot be ruled out taking into account the related mechanism of action (increase in serotonin concentrations).</p><p>Caution should be exercised when prescribing to pregnant women. If mirtazapine is used until, or shortly before birth, postnatal monitoring of the newborn is recommended to account for possible discontinuation effects.</p><p><u>Breast-feeding</u></p><p>Animal studies and limited human data have shown excretion of mirtazapine in breast milk only in very small amounts. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with mirtazapine should be made taking into account the benefit of breastfeeding to the child and the benefit of mirtazapine therapy to the woman.</p><p><u>Fertility</u></p><p>Non-clinical reproductive toxicity studies in animals did not show any effect on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>Mirtazapine has minor or moderate influence on the ability to drive and use machines. Mirtazapine may impair concentration and alertness (particularly in the initial phase of treatment). Patients should avoid the performance of potentially dangerous tasks, which require alertness and good concentration, such as driving a motor vehicle or operating machinery, at any time when affected.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>Depressed patients display a number of symptoms that are associated with the illness itself. It is therefore sometimes difficult to ascertain which symptoms are a result of the illness itself and which are a result of treatment with Mirzagen.</p><p>The most commonly reported adverse reactions, occurring in more than 5 % of patients treated with Mirzagen in randomized placebo-controlled trials (see below) are somnolence, sedation, dry mouth, weight increased, increase in appetite, dizziness and fatigue.</p><p>All randomized placebo-controlled trials in patients (including indications other than major depressive disorder), have been evaluated for adverse reactions of Mirzagen. The meta-analysis considered 20 trials, with a planned duration of treatment up to 12 weeks, with 1,501 patients (134 person years) receiving doses of mirtazapine up to 60 mg and 850 patients (79 person years) receiving placebo. Extension phases of these trials have been excluded to maintain comparability to placebo treatment.</p><p>Table 1 shows the categorized incidence of the adverse reactions, which occurred in the clinical trials statistically significantly more frequently during treatment with Mirzagen than with placebo, added with adverse reactions from spontaneous reporting. The frequencies of the adverse reactions from spontaneous reporting are based on the reporting rate of these events in the clinical trials. The frequency of adverse reactions from spontaneous reporting for which no cases in the randomized placebo-controlled patient trials were observed with mirtazapine has been classified as &#39;not known&#39;.</p><p><strong>Table 1. Adverse reactions of Mirzagen</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>(&ge;1/10)</strong></p></td><td style="vertical-align:top; width:104px"><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top; width:142px"><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1,000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;1/10,000 to &lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Blood and the lymphatic system disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull; Bone marrow depression (granulocytopenia, agranulocytosis, aplastic anaemia, thrombocytopenia)</p><p>&bull; Eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Endocrine disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull; Inappropriate antidiuretic hormone secretion</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders</em></strong></p></td><td style="vertical-align:top"><p>&bull; Weight increased<sup>1</sup></p><p>&bull; Increase in appetite<sup>1</sup></p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull; Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Psychiatric disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&bull; Abnormal dreams</p><p>&bull; Confusion</p><p>&bull; Anxiety<sup>2, 5</sup></p><p>&bull; Insomnia<sup>3, 5</sup></p></td><td style="vertical-align:top; width:142px"><p>&bull; Nightmares<sup>2</sup></p><p>&bull; Mania</p><p>&bull; Agitation<sup>2</sup></p><p>&bull; Hallucinations</p><p>&bull; Psychomotor restlessness (incl. akathisia, hyperkinesia)</p></td><td style="vertical-align:top"><p>&bull; Aggression</p></td><td style="vertical-align:top"><p>&bull; Suicidal ideation<sup>6</sup></p><p>&bull; Suicidal behaviour<sup>6</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Nervous system disorders</em></strong></p></td><td style="vertical-align:top"><p>&bull; Somnolence<sup>1, 4</sup></p><p>&bull; Sedation<sup>1, 4</sup></p><p>&bull; Headache<sup>2</sup></p></td><td style="vertical-align:top; width:104px"><p>&bull; Lethargy<sup>1</sup></p><p>&bull; Dizziness</p><p>&bull; Tremor &bull;Amnesia*</p></td><td style="vertical-align:top; width:142px"><p>&bull; Paraesthesia<sup>2</sup></p><p>&bull; Restless legs</p><p>&bull; Syncope</p></td><td style="vertical-align:top"><p>&bull; Myoclonus</p></td><td style="vertical-align:top"><p>&bull; Convulsions (insults)</p><p>&bull; Serotonin syndrome</p><p>&bull; Oral paresthaesia</p><p>&bull; Dysarthia</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Vascular disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&bull; Orthostatic hypotension</p></td><td style="vertical-align:top; width:142px"><p>&bull; Hypotension<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gastrointestinal disorders</em></strong></p></td><td style="vertical-align:top"><p>&bull; Dry mouth</p></td><td style="vertical-align:top; width:104px"><p>&bull; Nausea<sup>3</sup></p><p>&bull; Diarrhea<sup>2</sup></p><p>&bull; Vomiting<sup>2</sup></p><p>&bull; Constipation<sup>1</sup></p></td><td style="vertical-align:top; width:142px"><p>&bull; Oral hypoaesthesia</p></td><td style="vertical-align:top"><p>&bull; Pancreatitis</p></td><td style="vertical-align:top"><p>&bull; Mouth oedema</p><p>&bull; Increased salivation</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Hepatobiliary disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull; Elevations in serum transaminase activities</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&bull; Exanthema<sup>2</sup></p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull; Stevens-Johnson Syndrome</p><p>&bull; Dermatitis bullous</p><p>&bull; Erythema multiforme</p><p>&bull; Toxic epidermal necrolysis</p><p>&bull; Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&bull; Arthralgia</p><p>&bull; Myalgia</p><p>&bull; Back pain<sup>1</sup></p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull; Rhabdomyolysis</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Renal and urinary disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull; Urinary retention</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>General disorders and administration site conditions</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&bull; Oedema peripheral<sup>1</sup></p><p>&bull; Fatigue</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull; Somnambulism</p><p>&bull; Generalised oedema</p><p>&bull; Localised oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Investigations</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull; Increased creatine kinase</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;In clinical trials these events occurred statistically significantly more frequently during treatment with Mirzagen than with placebo.</p><p><sup>2</sup>&nbsp;In clinical trials these events occurred more frequently during treatment with placebo than with Mirzagen, however not statistically significantly more frequently.</p><p><sup>3</sup>&nbsp;In clinical trials these events occurred statistically significantly more frequently during treatment with placebo than with Mirzagen.</p><p><sup>4</sup>N.B. dose reduction generally does not lead to less somnolence/sedation but can jeopardize antidepressant efficacy.</p><p><sup>5</sup>&nbsp;Upon treatment with antidepressants in general, anxiety and insomnia (which may be symptoms of depression) can develop or become aggravated. Under mirtazapine treatment, development or aggravation of anxiety and insomnia has been reported.</p><p><sup>6</sup>&nbsp;Cases of suicidal ideation and suicidal behaviours have been reported during mirtazapine therapy or early after treatment discontinuation (see section 4.4).</p><p>In laboratory evaluations in clinical trials transient increases in transaminases and gamma-glutamyltransferase have been observed (however associated adverse events have not been reported statistically significantly more frequently with Mirzagen than with placebo).</p><p><u>Paediatric population</u></p><p>The following adverse events were observed commonly in clinical trials in children: weight gain, urticaria and hypertriglyceridaemia (see also section 5.1).</p><p>*In most cases patients recovered after drug withdrawal.</p><p>** Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), bullous dermatitis and erythema multiforme have been reported in association with Mirzagen treatment</p><p><u>Please report adverse drug events to: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Present experience concerning overdose with Mirzagen alone indicates that symptoms are usually mild. Depression of the central nervous system with disorientation and prolonged sedation have been reported, together with tachycardia and mild hyper- or hypotension. However, there is a possibility of more serious outcomes (including fatalities) at dosages much higher than the therapeutic dose, especially with mixed overdoses. In these cases QT prolongation and Torsade de Pointes have also been reported.</p><p>Cases of overdose should receive appropriate symptomatic and supportive therapy for vital functions. ECG monitoring should be undertaken. Activated charcoal or gastric lavage should also be considered.</p><p><u>Paediatric population</u></p><p>The appropriate actions as described for adults should be taken in case of an overdose in paediatrics.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>&nbsp;</p></td><td><p>Pharmacotherapeutic group: other antidepressants, ATC code: N06AX11</p><p><u>Mechanism of action/pharmacodynamic effects</u></p><p>Mirtazapine is a centrally active presynaptic &alpha;2-antagonist, which increases central noradrenergic and serotonergic neurotransmission. The enhancement of serotonergic neurotransmission is specifically mediated via 5-HT1 receptors, because 5-HT2 and 5-HT3 receptors are blocked by mirtazapine. Both enantiomers of mirtazapine are presumed to contribute to the antidepressant activity, the S(+) enantiomer by blocking &alpha;2 and 5-HT2 receptors and the R(-) enantiomer by blocking 5-HT3 receptors.</p><p><u>Clinical efficacy and safety</u></p><p>The histamine H1-antagonistic activity of mirtazapine is associated with its sedative properties. It has practically no anticholinergic activity and, at therapeutic doses, has only limited effects (e.g. orthostatic hypotension) on the cardiovascular system.</p><p><u>Paediatric population</u></p><p>Two randomised, double-blind, placebo-controlled trials in children aged between 7 and 18 years with major depressive disorder (n=259) using a flexible dose for the first 4 weeks (15-45 mg mirtazapine) followed by a fixed dose (15, 30 or 45 mg mirtazapine) for another 4 weeks failed to demonstrate significant differences between mirtazapine and placebo on the primary and all secondary endpoints. Significant weight gain (&ge;7%) was observed in 48.8% of the Mirzagen SolTab treated subjects compared to 5.7% in the placebo arm. Urticaria (11.8% vs. 6.8%) and hypertriglyceridaemia (2.9% vs. 0%) were also commonly observed.</p></td><td><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p><u>Absorption</u></p><p>After oral administration of Mirzagen SolTab, the active substance mirtazapine is rapidly and well absorbed (bioavailability &asymp; 50 %), reaching peak plasma levels after approx. two hours. Food intake has no influence on the pharmacokinetics of mirtazapine.</p><p><u>Distribution</u></p><p>Binding of mirtazapine to plasma proteins is approx. 85 %.</p><p><u>Biotransformation</u></p><p>Major pathways of biotransformation are demethylation and oxidation, followed by conjugation. In vitro data from human liver microsomes indicate that cytochrome P450 enzymes CYP2D6 and CYP1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas CYP3A4 is considered to be responsible for the formation of the N-demethyl and N-oxide metabolites. The demethyl metabolite is pharmacologically active and appears to have the same pharmacokinetic profile as the parent compound.</p><p><u>Elimination</u></p><p>Mirtazapine is extensively metabolized and eliminated via the urine and faeces within a few days. The mean half-life of elimination is 20-40 hours; longer half-lives, up to 65 hours, have occasionally been recorded and shorter half-lives have been seen in young men. The half-life of elimination is sufficient to justify once-a-day dosing. Steady state is reached after 3-4 days, after which there is no further accumulation.</p><p><u>Linearity/non-linearity</u></p><p>Mirtazapine displays linear pharmacokinetics within the recommended dose range.</p><p><u>Special populations</u></p><p>The clearance of mirtazapine may be decreased as a result of renal or hepatic impairment.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>&nbsp;</p></td><td><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p><p>In reproductive toxicity studies in rats and rabbits no teratogenic effects were observed. At two-fold systemic exposure compared to maximum human therapeutic exposure, there was an increase in post-implantation loss, decrease in the pup birth weights, and reduction in pup survival during the first three days of lactation in rats.</p><p>Mirtazapine was not genotoxic in a series of tests for gene mutation and chromosomal and DNA damage. Thyroid gland tumours found in a rat carcinogenicity study and hepatocellular neoplasms found in a mouse carcinogenicity study are considered to be species-specific, non-genotoxic responses associated with long-term treatment with high doses of hepatic enzyme inducers.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>&nbsp;</p></td><td><p><em>Core</em>:</p><p>Lactose anhydrous</p><p>Maize starch</p><p>Colloidal anhydrous silica</p><p>Low substituted HPC (LH-21)</p><p>Magnesium stearate.</p><p><em>Coating:</em></p><p>15mg: Opadry yellow 31K52613</p><p>30mg: Opadry Buff OY-IS-37200</p><p>45mg: Opadry white OY-IS-28908</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package to protect from light &amp; moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>Pack of Mirzagen 30 mg &nbsp;tablets contains 30 film coated tablets: 3 white blisters (PVC/PVDC/Alu), each blister contains 10 film coated tablets.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of reach of children</p><p>No other special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O.Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                   6/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>